Rafael Holdings' Phase 3 NPC trial misses primary endpoint, subgroup hits significanceSep 30Clinical readoutRafael Holdings, Inc.
Amicus reports FY2025 results as BioMarin merger deal proceedsJul 13PeopleBiomarin Pharmaceutical Inc
Sign inSign in